ASP Isotopes Stock Price, News & Analysis

ASP Isotopes (NASDAQ: ASPI) priced an underwritten public offering of 17,167,380 shares of common stock for gross proceeds of approximately $210.3 million, before underwriting discounts, commissions and offering expenses.

The offering is expected to close on October 16, 2025, subject to customary closing conditions. The company granted the underwriters a 30‑day option to purchase additional shares for approximately $31.5 million at the offering price. Cantor and Lucid Capital Markets are joint book‑running managers. The company intends to use net proceeds for general corporate purposes including working capital, operating expenses and capital expenditures.

ASP Isotopes (NASDAQ: ASPI) announced on October 14, 2025 that it is commencing an underwritten public offering of common stock. The offering is subject to market conditions and there is no assurance as to timing, size, or terms.

Cantor and Lucid Capital Markets are acting as joint book-running managers. The offering is being made from a shelf registration statement filed with the SEC on October 14, 2025, which became effective upon filing. A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC and will be available at www.sec.gov.

Copies of the preliminary prospectus supplement and prospectus, when available, may be requested from Cantor Fitzgerald or Lucid Capital Markets. This press release is not an offer to sell or a solicitation to buy securities.

ASP Isotopes (NASDAQ: ASPI) announced a supply contract for its largest quantity of enriched silicon-28 to date, with deliveries expected in Q1 2026, and the acquisition of an independent radiopharmacy in Florida, US to expand PET Labs' operations outside South Africa.

The Florida site currently offers SPECT; PET services are expected to start in 2027. The acquisition is described as accretive to 2026 revenues, EBITDA and EPS. PET Labs is pursuing further U.S. expansion and has a non-binding term sheet for another acquisition. An investor access event is scheduled for Nov 12-13, 2025. The company also granted a 30,000-share restricted stock inducement vesting semi-annually over four years.

ASP Isotopes (NASDAQ: ASPI) will host an Institutional Investor Access Event in South Africa from November 11–13, 2025, with a possible optional visit to the Renergen Virginia Gas Project on November 14, 2025 (subject to numbers).

Limited places remain. Attendees cover their own flight and hotel costs. The agenda includes scientific sessions, plant tours of three enrichment production plants and PET Labs, management and scientific-team presentations, and Q&A. Suggested travel timing enables U.S. departures on Nov 10 (evening) and return Nov 14 (morning).

Register by emailing vpetkov@aspisotopes.com. Attendees must submit a copy of their passport by October 21, 2025 for required security clearances; registrations are subject to availability and company acceptance.

ASP Isotopes (NASDAQ:ASPI) has secured a purchase order from a U.S.-based customer for enriched Barium-137, scheduled for delivery in Q1 2026. The isotope is crucial for ion-trap quantum computing, offering a stable qubit platform and improved operational reliability for quantum processors.

Enriched Barium-137's favorable optical properties, operating in visible-light wavelengths, facilitate integration with existing hardware and support quantum networking developments. The company positions this achievement as part of its strategy to become a leading supplier of advanced materials to the quantum computing industry, alongside other industrial isotopes like Silicon-28.

ASP Isotopes (NASDAQ:ASPI), an advanced materials company focused on isotope production, announced significant leadership changes effective October 1, 2025. Founder and CEO Paul Mann will transition to Executive Chairman and take a temporary health-related leave, following complications from orthopedic surgery. Robert Ainscow, the company's COO, has been appointed Interim CEO.

Additionally, Michael Cunniffe will join Quantum Leap Energy LLC as CFO, preparing for its upcoming public listing. The company also announced two investor events: an Institutional Investor Access Event in South Africa on November 12-13, 2025, and a Quarterly Business Update webinar in November 2025.

ASP Isotopes (NASDAQ:ASPI) has appointed nuclear industry veteran Ralph L. Hunter, Jr. to its board of directors and to the board of managers of Quantum Leap Energy LLC. Hunter brings over 30 years of nuclear power industry experience in leadership roles and significant expertise in nuclear technology development.

Hunter's impressive background includes serving as Chair of the US Civil Nuclear Trade Advisory Committee (CINTAC), board membership at Rolls-Royce SMR Limited, and leadership positions at Constellation Energy. He currently serves as Chairman and CEO of RC Nuclear Consultants, LLC, which he established in June 2025.

The appointment aligns with ASP Isotopes's plans to apply its enrichment technologies to uranium production for next-generation nuclear reactors.

ASP Isotopes (NASDAQ:ASPI) has achieved significant milestones, transitioning from R&D to commercial operations with three operational isotope enrichment facilities. The company has successfully shipped its first Ytterbium-176 and Silicon-28 samples to customers, projecting $50-70 million in potential revenues for 2026-2027 from these isotopes alone.

Key developments include: Quantum Leap Energy's planned Q4 2025 IPO, a strategic MOU with Fermi America for nuclear fuel facilities, PET Labs' record-breaking performance, and the anticipated Renergen merger closing in Q3 2025. The company has expanded its management team to over 170 employees and targets $300 million in EBITDA by 2030. Additionally, ASPI recently listed on the Johannesburg Stock Exchange (JSE: ISO) to enhance liquidity and access capital markets.

[ "Successfully shipped first Ytterbium-176 and Silicon-28 samples with $50-70M potential revenue for 2026-2027", "Three isotope enrichment facilities now operational with four new laser plants planned", "Strategic MOU with Fermi America for nuclear fuel facilities development", "PET Labs achieving record performance with second cyclotron operational", "Renergen merger expected to be highly accretive to revenue, EBITDA, and EPS in 2026", "Management projects $300M EBITDA target by 2030", "Institutional ownership increased to over 70%", "Successful dual-listing on Johannesburg Stock Exchange" ]

ASP Isotopes (NASDAQ:ASPI) hosted South African investors ahead of its secondary listing on the Johannesburg Stock Exchange (JSE), scheduled for August 27, 2025. The company provided significant updates on multiple isotope production facilities:

The company has shipped its first Silicon-28 samples to a US customer and expects to complete Ytterbium-176 enrichment in August 2025. Their Ytterbium facility is achieving a 52x enrichment factor, though facing a 3-4 week delay in transitioning to semi-continuous processing. The Carbon-14/12 facility is now producing 99.99% enriched Carbon-12, with first commercial delivery expected in September 2025.

Additionally, ASP Isotopes continues to progress on two major corporate initiatives: the planned spin-out of Quantum Leap Enrichment (QLE) in H2 2025 and the anticipated closure of the Renergen acquisition in Q3 2025.